Limbix is moving ahead with plans to file for FDA approval of its SparkRx digital therapeutic (DTx) for adolescents with symptoms of depression after reporting positive results in a clinica
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh